# RNN 1st Gen Model Regeneron Pharmaceuticals, Inc. Pharmaceutical preparations
May 3, 2018
at 15-mar-2019
REGN
Model's trade recommendations 3.06% Return for period
-4.68% Annual return
$31.89B Market Cap
β 1.44
REGN
Model (following trade recommendations)REGN
Underlying stockS&P 500
Index- BUY Analysts consensus recommendation
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Regeneron Pharmaceuticals, Inc. (REGN) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 22, 2015.
Market data for REGN model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 94M |
| P/E | 21.43 |
| Shares Outstanding | 108M |
| % Held by Insiders | 12.42% |
| % Held by Institutions | 66.37% |
| EPS (last reported FY) | $13.41 |
| EPS (last reported Q) | $4.46 |
| EPS, estimated (last reported Q) | $4.18 |
| Total revenues | $6 B |
| Net income | $1 B |